Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. in British journal of haematology / Br J Haematol. 2025 Mar;206(3):924-929. doi: 10.1111/bjh.19976. Epub 2025 Jan 7.
2025
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
Tipo pubblicazione
Multicenter Study
Autori/Collaboratori (18)Vedi tutti...
Vitale C
University Division of Hematology, A.O.U. Città Della Salute e Della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Coscia M
University Division of Hematology, A.O.U. Città Della Salute e Della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Bruno B
Department of Oncology and Hematology University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy.
et alii...
University Division of Hematology, A.O.U. Città Della Salute e Della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Coscia M
University Division of Hematology, A.O.U. Città Della Salute e Della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Bruno B
Department of Oncology and Hematology University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy.
et alii...
Abstract
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains an option for young and fit chronic lymphocytic leukaemia (CLL) patients with high-risk disease features. However, allotransplanted patients are generally excluded from clinical trials, making data regarding the use of venetoclax after alloHSCT extremely rare. We report data from 7 CLL patients who received venetoclax after alloHSCT among 53 Italian centers. These patients underwent alloHSCT between 2006 and 2021 after failing chemoimmunotherapy (7/7), ibrutinib (5/7) and/or idelalisib (1/7). Of note, 3/7 patients had already received venetoclax-based therapy before alloHSCT. Post-allo HSCT venetoclax treatment resulted safe, with adverse events not different from what reported in clinical trials. Importantly, no meaningful impact on graft versus host disease (GvHD) course was observed: 4/7 patients with pre-existing chronic GvHD had no exacerbation after venetoclax start, and only one patient developed GvHD during venetoclax therapy, that was managed as per standard clinical practice. Concerning efficacy, 5/7 patients presented a clinical response to venetoclax, with two patients achieving an undetectable minimal residual disease. To our knowledge, this is the largest reported series of CLL patients treated with venetoclax after alloHSCT. In these heavily pretreated and high-risk patients, previous alloHSCT did not compromise the feasibility of venetoclax therapy, that lacked unexpected toxicities and did not exacerbate GvHD.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.
PMID : 39777647
DOI : 10.1111/bjh.19976
Keywords
Recurrence; Graft vs Host Disease/etiology; Aged; Transplantation, Homologous; Middle Aged; Female; Male; Hematopoietic Stem Cell Transplantation; Sulfonamides/therapeutic use/administration & dosage; Leukemia, Lymphocytic, Chronic, B-Cell/therapy/drug therapy; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use/administration & dosage/adverse effects; Humans; Adult; Antineoplastic Agents/therapeutic use/adverse effects/administration & dosage; chronic lymphocytic leukaemia; stem cell transplantation; venetoclax;